In the last decade, the first-in-class covalent BTK inhibitor ibrutinib has shown remarkable activity both in previously treated and untreated CLL patients, thus progressively replacing traditional chemotherapy-based regimens [5,6,7,8,9]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.